Septerna, Inc. (NASDAQ:SEPN) Stock Has Consensus Price Target of $52.44 According to Brokerages

Septerna, Inc. (NASDAQ:SEPN) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $52.44.

A number of equities research analysts have recently weighed in on SEPN shares. JonesTrading lifted their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Thursday. HC Wainwright lifted their price objective on shares of Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Truist Financial boosted their price target on Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Finally, Guggenheim lifted their target price on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th.

Insider Transactions at Septerna

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $7,665,196. This represents a 12.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Daniel D. Long sold 3,333 shares of Septerna stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the transaction, the senior vice president directly owned 96,412 shares of the company’s stock, valued at $3,647,265.96. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 31,667 shares of company stock worth $1,341,010 over the last three months. Insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently modified their holdings of the business. TRV GP V LLC acquired a new position in shares of Septerna during the second quarter valued at about $208,160,143. TRV GP VI LLC bought a new stake in Septerna during the 2nd quarter valued at $141,048,460. BlackRock Inc. bought a new stake in shares of Septerna during the second quarter worth about $64,706,000. Jupiter Topco LLC acquired a new stake in shares of Septerna in the 2nd quarter worth about $43,723,000. Finally, Primecap Management Co. CA bought a new stake in Septerna during the 2nd quarter worth approximately $39,096,000.

Septerna Trading Down 2.9%

Shares of NASDAQ SEPN opened at $36.35 on Friday. Septerna has a 12 month low of $17.55 and a 12 month high of $51.10. The stock has a 50 day moving average of $39.30 and a 200-day moving average of $33.50. The company has a market capitalization of $1.70 billion, a P/E ratio of -67.31 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. Analysts predict that Septerna will post -1.41 EPS for the current fiscal year.

Septerna Company Profile

Septerna, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address.